Rebecca Quiroz, MD
Internal Medicine · San Antonio, TXNPI 1235293457
Payments from drug & device makers
Across 110 payments — averaging $64.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Baxter Healthcare$4K
- Welch Allyn$2K
- AstraZeneca$419
- Pfizer$231
- GSK$172
- Merck$170
- plus $998 from 23 others
What the payments were for
- Food & beverage$1,99028%
- Other$5,09772%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Baxter Healthcare | 2 | $3,522 |
| Welch Allyn | 1 | $1,575 |
| AstraZeneca | 20 | $419 |
| Pfizer | 13 | $231 |
| GSK | 9 | $172 |
| Merck | 9 | $170 |
| Novo Nordisk | 10 | $159 |
| Lilly USA, LLC | 8 | $146 |
| Abbott | 4 | $77 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $70 |
| Idorsia Pharmaceuticals US Inc | 4 | $68 |
| Exact Sciences | 3 | $65 |
| AbbVie | 2 | $41 |
| Astellas Pharma US Inc | 2 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Medtronic | 2 | $34 |
| Corcept Therapeutics | 2 | $31 |
| Biohaven Pharmaceuticals, Inc. | 1 | $24 |
| Corium, LLC | 1 | $23 |
| Bayer | 1 | $22 |
| Shire North American Group Inc | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $20 |
| Gilead | 1 | $19 |
| Shield Therapeutics Inc | 1 | $18 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Nalpropion Pharmaceuticals LLC | 1 | $15 |
| Eisai Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CardioPerfect PRO ECG Recorder$1,575
- FARXIGA$125
How this compares
$7,087 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 49 | $61,936 |
| EliquisApixaban | 29 | $48,452 |
| FarxigaDapagliflozin Propanediol | 24 | $32,633 |
| MounjaroTirzepatide | 18 | $20,674 |
| RybelsusSemaglutide | 18 | $18,929 |
| JanuviaSitagliptin Phosphate | 12 | $18,280 |
| XareltoRivaroxaban | 12 | $17,747 |
| MyrbetriqMirabegron | 15 | $13,904 |
| LunestaEszopiclone | 13 | $10,470 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $4,115 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $4,059 |
| Estradiol | 24 | $3,540 |
| Levothyroxine Sodium | 221 | $2,131 |
| ProgesteroneProgesterone, Micronized | 27 | $1,837 |
| Bupropion XlBupropion Hcl | 52 | $1,816 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $159 | $80,86567 claims |
| PfizerEliquis | $231 | $48,45229 claims |
| AstraZenecaFarxiga, Symbicort | $419 | $36,69235 claims |
| Lilly USA, LLCMounjaro | $146 | $20,67418 claims |
| MerckJanuvia | $170 | $18,28012 claims |
| Astellas Pharma US IncMyrbetriq | $40 | $13,90415 claims |
| AbbVieSynthroid, Armour Thyroid | $41 | $2,80729 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in San Antonio
- Robert BassSan Antonio$25.6M
- Hernan SalazarSan Antonio$18.5M
- Dennis RuffSan Antonio$7.5M
- Cassandra KeySan Antonio$5.6M
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.